SNSS Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 40th Annual Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 AM Eastern Standard Time in Boston, Massachusetts. The presentation will be followed by a 30-minute breakout session at 10:40 AM Eastern Standard Time.

A live webcast of the presentation and breakout session will be available on the Sunesis website at http://ir.sunesis.com.  A replay will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including its oral non-covalent BTK inhibitor vecabrutinib and PDK1 inhibitor SNS-510. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc. 

Investor and Media Inquiries:Maeve ConneightonArgot Partners212-600-1902

Willie QuinnSunesis Pharmaceuticals Inc.650-266-3716